{"cluster": 36, "subcluster": 63, "abstract_summ": "Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8+ T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment.To elucidate pathways in peripheral immune cells that might lead to immunopathology or protective immunity in severe COVID-19, we applied single-cell RNA sequencing (scRNA-seq) to profile peripheral blood mononuclear cells (PBMCs) from seven patients hospitalized for COVID-19, four of whom had acute respiratory distress syndrome, and six healthy controls.Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients.Collectively, we provide the most thorough cell atlas to date of the peripheral immune response to severe COVID-19.SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease.Approximately 20% of patients with COVID-19 develop severe disease and 5% of patients require intensive care2.", "title_summ": "A single-cell atlas of the peripheral immune response in patients with severe COVID-19.Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early prognostic marker for severe COVID-19Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by TocilizumabViable circulating endothelial cells and their progenitors are increased in Covid-19 patientsA single-cell atlas of the peripheral immune response to severe COVID-19Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)Immunological and inflammatory profiles in mild and severe cases of COVID-19", "title_abstract_phrases": "Collectively, we provide the most thorough cell atlas to date of the peripheral immune response to severe COVID-19.Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)SARS-CoV-2 is associated with a 3.4% mortality rate in patients with severe disease.Although Tocilizumab treatment attenuated the strong inflammatory immune response, we found that immune cells including plasma B cells and CD8+ T cells still exhibited an intense humoral and cell-mediated anti-virus immune response in COVID-19 patients after Tocilizumab treatment.To elucidate pathways in peripheral immune cells that might lead to immunopathology or protective immunity in severe COVID-19, we applied single-cell RNA sequencing (scRNA-seq) to profile peripheral blood mononuclear cells (PBMCs) from seven patients hospitalized for COVID-19, four of whom had acute respiratory distress syndrome, and six healthy controls.Here, by employing single-cell analysis of the immune cell composition of severe-stage COVID-19 patients and these same patients in post Tocilizumab-treatment remission, we have identified a monocyte subpopulation specific to severe disease that contributes to inflammatory storms in COVID-19 patients.Approximately 20% of patients with COVID-19 develop severe disease and 5% of patients require intensive care2."}